Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
American Society for Bone and Mineral Research (ASBMR) 2018 Annual Meeting
September 28 - October 01, 2018; Montreal, Quebec
September 28 - October 01, 2018Montreal, Quebec
ASBMR 2018Can Rare Rebound Fractures After Denosumab Therapy Be Avoided?Two studies suggest rare rebound vertebral fractures after stopping denosumab may be averted by giving a potent bisphosphonate and not continuing aromatase inhibitors beyond 6 months of stopping.
Medscape Medical News, October 22, 2018
ASBMR 2018Are Osteoporosis Drugs Linked With Survival? Debate Casts DoubtThe mortality benefit of osteoporosis drugs is "probably around 10%," claims one expert. However, strong evidence to support prescribing these drugs for this reason "is just not there," says another.
Extended DXA, Risk Factors, Predict AFF With Bisphosphonate UseTwo new studies indicate novel ways to help identify or predict the small percentage of osteoporosis patients using bisphosphonates
who will be adversely affected by atypical femoral fractures.